Ronen Ben‐ami - Infectious Diseases

Author Information

Ronen Ben-Ami is affiliated with the Infectious Diseases Unit at the Tel Aviv Sourasky Medical Center, and also holds a position at the Sackler Faculty of Medicine, Tel Aviv University in Tel Aviv, Israel. His expertise in infectious diseases is demonstrated through his extensive research work and contributions to the field.

Research Contributions

Ronen Ben-Ami has made significant contributions to the field of infectious diseases, focusing on various aspects such as the clinical features and outcomes of infections, vaccine immunogenicity, and the treatment of resistant infections. His work includes studies on Campylobacteriosis, Candida bloodstream infections, and the immunogenicity and safety of COVID-19 vaccines, particularly the BNT162b2 mRNA vaccine. He has also contributed to research on the effects of treatments like Tocilizumab on inflammatory markers in patients with serious infections.

Aliases

Ronen Ben-Ami is also known in publications and research circles by several aliases, including R Ben-Ami, R Ben-ami, and R Ben–ami.

Publication and Citation Metrics

Metric	Value
Citation Count	7101
H-index	40
Paper Count	170

Publications:

Clinical features and outcomes of bacteremic and non-bacteremic Campylobacteriosis: a case–control study

DOI: 10.1007/s15010-022-01798-8

Year: 2022

Immunogenicity of a Third Dose of the BNT162b2 mRNA Covid-19 Vaccine in Patients with Impaired B Cell Reconstitution After Cellular Therapy—A Single Center Prospective Cohort Study

DOI: 10.1016/j.jtct.2022.02.012

Year: 2022

Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel.

DOI: 10.1001/jama.2021.23641

Year: 2022

Frequency and Clinical Features of Candida Bloodstream Infection Originating in the Urinary Tract

DOI: 10.3390/jof8020123

Year: 2022

Short-Term Safety of Booster Immunization With BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers

DOI: 10.1093/ofid/ofab656

Year: 2022

The effect of a third-dose BNT162b2 vaccine on anti-SARS-CoV-2 antibody levels in immunosuppressed patients

DOI: 10.1016/j.cmi.2022.02.002

Year: 2022

Piperacillin–tazobactam versus meropenem for treatment of bloodstream infections caused by third-generation cephalosporin-resistant Enterobacteriaceae: a study protocol for a non-inferiority open-label randomised controlled trial (PeterPen)

DOI: 10.1136/bmjopen-2020-040210

Year: 2021

The Effect of Tocilizumab on Inflammatory Markers in Patients Hospitalized with Serious Infections. Case Series and Review of Literature

DOI: 10.3390/life11030258

Year: 2021

Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel

DOI: 10.1056/NEJMoa2109730

Year: 2021

Immunogenicity of a BNT162b2 vaccine booster in health-care workers

DOI: 10.1016/S2666-5247(21)00272-X

Year: 2021

What is the Future of PCR in Infectious Diseases?

What Are the Risks to the Fetus?

What are the challenges in HIV prevention?

What Are Some of WHO’s Recent Initiatives in Infectious Disease Control?

How Does Personalized Medicine Apply to Infectious Diseases?

How is Salmonella Transmitted?

What Should You Do if You Suspect Contamination?

How Can Dengue Be Prevented?

How is Lyme Disease Diagnosed?

What is the Role of Public Health in Managing Gonorrhea?

Partnered Content Networks

Relevant Topics